Detail

Description

Expression Detail
Experiment ID:
EXP00225
Reference:
  • Title: Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
  • Author: Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, "DAuria F", Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, "Omede P", Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research.2013 Jun 15;19(12):3130-42.doi:10.1158/1078-0432.CCR-12-2043.
  • Abstract: Primary plasma cell leukemia (pPCL) is a rare and very aggressive form of plasma cell dyscrasia. To date, no information on microRNA (miRNA) expression in pPCL has been reported. This study aimed at investigating the involvement of miRNAs in pPCL and their possible relationship with higher tumor aggressiveness., Global miRNA expression profiles were analyzed in highly purified malignant plasma cells from 18 pPCL untreated patients included in a prospective clinical trial. MiRNA expression patterns were evaluated in comparison with a representative series of multiple myeloma patients, in relation to the most recurrent chromosomal abnormalities (as assessed by fluorescence in situ hybridization and single-nucleotide polymorphism-array analysis), and in association with clinical outcome. MiRNA expression was also integrated with gene expression profiles in pPCL and multiple myeloma samples., We identified a series of deregulated miRNAs in pPCL (42 upregulated and 41 downregulated) in comparison with multiple myeloma. Some of them, on the basis of their reported functions and putative target genes computed by integrative analysis, might have a role in the pathobiology of pPCL. As regards chromosomal aberrations, the expression of some miRNAs mapped to hotspot altered regions was associated with DNA copy number of the corresponding loci. Finally, 4 miRNA (miR-497, miR-106b, miR-181a*, and miR-181b) were identified as having expression levels that correlated with treatment response, and 4 (miR-92a, miR-330-3p, miR-22, and miR-146a) with clinical outcome., Overall, our study provides insights into the possible contribution of miRNAs in the pathogenesis of pPCL and suggests targets for future therapeutic investigations.
  • PMID: 23613318
Expression Profile:
  • Description:Patterns of miRNA expression in primary plasma cell leukemias: implications for tumor progression in multiple myeloma
  • Organism:Homo sapiens
  • Source:GEO
  • Source ID:GSE37053
  • Platform: GPL8227
  • Number of samples:57
  • Overall design:This series of microarray experiments contains the microRNA profiles of purified plasma cells (PCs) obtained from 39 multiple myeloma (MM) and 18 primary plasma cell leukemia (pPCL) at diagnosis. PCs were purified from bone marrow specimens, after red blood cell lysis with 0.86% ammonium chloride, using CD138 immunomagnetic microbeads. The purity of the positively selected PCs was assessed by morphology and flow cytometry and was > 90% in all cases. 500 nanograms of total RNA was processed in accordance with the manufacturer's protocols (Agilent Technologies) to generate Cy3-labelled RNA, which were purified on chromatography columns (Micro Biospin 6, Bio-Rad, Hercules, CA) and then hybridized on an Agilent microarray (G4470B) at 55¡C for 17 hr in a rotating oven. Images at 5 um resolution were generated using an Agilent scanner G2505B. The Feature Extraction 10.7.3.1 software (Agilent Technologies) was used to obtain the microarray raw-data. The raw gTotalGeneSignal has been recalculated using the procedures described in Agilent Feature Extraction Software version 10.1 manual. Non-human probes, miRNAs flagged as ÒabsentÓ (i.e. expressed below background levels) throughout the whole dataset and miRNAs expired according to Sanger miRBase Release 15 (April 2010) were discarded, and a quantile normalization was applied on raw data using the aroma.light package for Bioconducor. The data were then converted to obtain positive values throughout the dataset, at a minimum value of 1, and log2 transformed.
  • Instrument:Agilent-019118 Human miRNA Microarray 2.0 G4470B (miRNA ID version)
Design and Sample:
  • Cancer Type:lymphoma
  • Cancer SubType:multiple myeloma
  • Cell Line:N/A
  • Experimental Design:subtype1 vs subtype2
  • Case Sample:multiple myeloma
  • Control Sample:leukemia
  • Num of Case:39
  • Num of Control:18
  • Quantification Software:Limma
  • Num of miRNAs:366
Identification:
  • Num of Up:69
  • Num of Down:66
Time Info:
  • Create Time2016-03-14
  • Update Time:2021-05-27

Differentially Expressed miRNAs List

Status:
miRNA ID Cancer Type Design logFC AveExpr T value P value adj Pvalue Status Plot

Functional Chart